Functionalization of Iron Oxide Magnetic Nanoparticles with the Multivalent Pseudopeptide N6l for Breast Tumor Targeting
Maha Sader1,2, Pierre Couleaud3,4, Gilles Carpentier1,2, Maud-Emmanuelle Gilles1,2, Noureddine Bousserrhine1,5, Alexandre Livet1,5, Ilaria Cascone1,2, Damien Destouches1,2, Aitziber L Cortajarena3,4 and José Courty1,2*
- *Corresponding Author:
- Dr. José Courty
Laboratory CRRET, EAC CNRS 7149
University Paris-Est, 61 Avenue du Général de Gaulle
94000 Créteil, France
Tel: +331 4517 1797
Fax: +331 4517 1816
E-mail: [email protected]
Received Date: June 08, 2015 Accepted Date: July 02, 2015 Published Date: July 12, 2015
Citation: Sader M, Couleaud P, Carpentier G, Gilles ME, Bousserrhine N, et al. (2015) Functionalization of Iron Oxide Magnetic Nanoparticles with the Multivalent Pseudopeptide N6l for Breast Tumor Targeting. J Nanomed Nanotechnol 6:299. doi:10.4172/2157-7439.1000299
Copyright: © 2015 Sader M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Functionalized iron oxide magnetic nanoparticles (MNP) are an innovative tool for cancer detection and treatment. In this study, a cell-surface nucleolin antagonist, N6L, was used as targeting ligand for MNP. This N6L, which exhibits antitumor activities, specifically targets bind tumor cells by binding to cell-surface nucleolin and glycosaminoglycans. N6L was covalently conjugated to dimercaptosuccinic acid coated magnetic nanoparticles (MNP-N6L). Using immunoprecipitation, gene invalidation and enzymatic degradation of glycosaminoglycans, we showed that MNP-N6L targets human breast cancer MDA-MB 231 cells through interaction with nucleolin and sulfated glycosaminoglycans. In vivo biodistribution studies were carried out in MDA-MB 231 tumor-bearing mice, using iron detection assay by spectrometric analysis and Prussian blue staining. Whereas both non-functionalized and functionalized nanoparticles were found in liver and spleen, only MNP-N6L was found in the tumor. Our findings indicate that MNP-N6L is a promising targeting system for theranostic applications in cancer detection and treatment.